These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10587291)

  • 1. Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma.
    Corona G; Aita P; Sorio R; Colussi AM; Bearz A; Sartor F; Boiocchi M; Toffoli G
    Anticancer Drugs; 1999 Oct; 10(9):815-9. PubMed ID: 10587291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
    Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
    Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
    Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
    Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
    Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
    McClay EF; Bogart J; Herndon JE; Watson D; Evans L; Seagren SL; Green MR;
    Am J Clin Oncol; 2005 Feb; 28(1):81-90. PubMed ID: 15685040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
    Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
    J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
    Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
    Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide.
    Sato H; Kitazawa H; Adachi I; Horikoshi I
    Pharm Res; 1996 Oct; 13(10):1565-9. PubMed ID: 8899852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
    Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
    Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic optimisation of treatment with oral etoposide.
    Toffoli G; Corona G; Basso B; Boiocchi M
    Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children.
    Eksborg S; Söderhäll S; Frostvik-Stolt M; Lindberg A; Liliemark E
    Anticancer Drugs; 2000 Apr; 11(4):237-41. PubMed ID: 10898537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
    Mross K; Bewermeier P; Reifke J; Krüger W; Stockschläder M; Zander A; Hossfeld DK
    Bone Marrow Transplant; 1994 Apr; 13(4):423-30. PubMed ID: 8019466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of grapefruit juice intake on etoposide bioavailability.
    Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
    Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.